S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)
S&P 500   4,274.51 (+0.02%)
DOW   33,550.27 (-0.20%)
QQQ   355.04 (+0.23%)
AAPL   170.43 (-0.89%)
MSFT   312.79 (+0.21%)
META   297.74 (-0.41%)
GOOGL   130.54 (+1.53%)
AMZN   125.98 (+0.00%)
TSLA   240.50 (-1.48%)
NVDA   424.68 (+1.33%)
NIO   8.47 (+0.71%)
BABA   86.19 (+0.33%)
AMD   98.07 (+2.20%)
T   14.88 (-0.93%)
F   12.39 (-0.32%)
MU   68.21 (+0.40%)
CGC   0.89 (-3.26%)
GE   110.85 (+0.84%)
DIS   79.89 (-0.20%)
AMC   7.57 (-4.30%)
PFE   32.11 (-0.93%)
PYPL   57.34 (-2.70%)
NFLX   377.59 (-0.44%)

Eyenovia (EYEN) Stock Forecast, Price & News

$1.70
+0.06 (+3.66%)
(As of 09/27/2023 ET)
Compare
Today's Range
$1.65
$1.72
50-Day Range
$1.57
$2.33
52-Week Range
$1.50
$5.85
Volume
185,966 shs
Average Volume
344,975 shs
Market Capitalization
$64.96 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.00

Eyenovia MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
618.6% Upside
$12.00 Price Target
Short Interest
Bearish
3.82% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
1.67mentions of Eyenovia in the last 14 days
Based on 3 Articles This Week
Insider Trading
Acquiring Shares
$90,264 Bought Last Quarter
Proj. Earnings Growth
Decreasing
From ($0.69) to ($0.80) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

404th out of 963 stocks

Pharmaceutical Preparations Industry

177th out of 451 stocks


EYEN stock logo

About Eyenovia (NASDAQ:EYEN) Stock

Eyenovia, Inc., a pre-commercial ophthalmic company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. It focuses on developing clinical microdosing of formulations of ophthalmic pharmaceutical agents using its Optejet branded targeted ocular delivery system. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi in rest of Asia. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is headquartered in New York, New York.

EYEN Price History

EYEN Stock News Headlines

Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
H.C. Wainwright Keeps Their Buy Rating on Eyenovia (EYEN)
Buy This Stock for AI Tidal Wave (not NVDA)
The internet boom made more millionaires than any tech  - Microsoft’s CEO says AI has even more potential. Here’s the #1 stock to buy.
H.C. Wainwright Remains a Buy on Eyenovia (EYEN)
Q2 2023 Eyenovia Inc Earnings Call
Eyenovia GAAP EPS of -$0.16 beats by $0.01
Earnings Preview For Eyenovia
EYEN - Eyenovia, Inc.
Eyenovia Expands Its US Manufacturing Capabilities
See More Headlines
Receive EYEN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Eyenovia and its competitors with MarketBeat's FREE daily newsletter.

EYEN Company Calendar

Last Earnings
8/10/2023
Today
9/27/2023
Next Earnings (Estimated)
11/09/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EYEN
Fax
N/A
Employees
41
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.00
High Stock Price Forecast
$12.00
Low Stock Price Forecast
$12.00
Forecasted Upside/Downside
+614.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

Net Income
$-28,010,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$14 million
Book Value
$0.48 per share

Miscellaneous

Free Float
35,231,000
Market Cap
$64.19 million
Optionable
Not Optionable
Beta
1.68
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Key Executives

  • Dr. Tsontcho Ianchulev M.D. (Age 49)
    M.P.H., MPH, Co-Founder & Exec. Chairman
    Comp: $920.87k
  • Mr. Michael M. Rowe (Age 61)
    CEO & Director
    Comp: $750.01k
  • Mr. John P. Gandolfo CPA (Age 62)
    CFO & Sec.
    Comp: $598.39k
  • Mr. Bren Kern (Age 42)
    COO & Corp. VP
  • Alexander Lobo
    Investor Contact













EYEN Stock - Frequently Asked Questions

Should I buy or sell Eyenovia stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Eyenovia in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" EYEN shares.
View EYEN analyst ratings
or view top-rated stocks.

What is Eyenovia's stock price forecast for 2023?

1 brokerages have issued 1 year price objectives for Eyenovia's shares. Their EYEN share price forecasts range from $12.00 to $12.00. On average, they expect the company's share price to reach $12.00 in the next twelve months. This suggests a possible upside of 614.3% from the stock's current price.
View analysts price targets for EYEN
or view top-rated stocks among Wall Street analysts.

How have EYEN shares performed in 2023?

Eyenovia's stock was trading at $1.63 at the beginning of 2023. Since then, EYEN shares have increased by 3.1% and is now trading at $1.68.
View the best growth stocks for 2023 here
.

Are investors shorting Eyenovia?

Eyenovia saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 1,460,000 shares, an increase of 9.8% from the August 31st total of 1,330,000 shares. Based on an average daily volume of 246,500 shares, the days-to-cover ratio is presently 5.9 days.
View Eyenovia's Short Interest
.

When is Eyenovia's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 9th 2023.
View our EYEN earnings forecast
.

How were Eyenovia's earnings last quarter?

Eyenovia, Inc. (NASDAQ:EYEN) released its quarterly earnings data on Thursday, August, 10th. The company reported ($0.16) EPS for the quarter, topping the consensus estimate of ($0.20) by $0.04.

What other stocks do shareholders of Eyenovia own?
When did Eyenovia IPO?

(EYEN) raised $30 million in an initial public offering on Thursday, January 25th 2018. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Ladenburg Thalmann and Roth Capital Partners​ served as the underwriters for the IPO.

What is Eyenovia's stock symbol?

Eyenovia trades on the NASDAQ under the ticker symbol "EYEN."

Who are Eyenovia's major shareholders?

Eyenovia's stock is owned by a number of retail and institutional investors. Top institutional shareholders include BlackRock Inc. (3.51%), Geode Capital Management LLC (1.46%), State Street Corp (1.16%), Renaissance Technologies LLC (1.12%), Northern Trust Corp (0.62%) and Nuveen Asset Management LLC (0.53%). Insiders that own company stock include Bren Kern, Charles E Iv Mather, Ellen R Strahlman, John P Gandolfo, Kenneth B Lee Jr, Michael M Rowe, Michael M Rowe, Stuart M Grant and Tsontcho Ianchulev.
View institutional ownership trends
.

How do I buy shares of Eyenovia?

Shares of EYEN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Eyenovia's stock price today?

One share of EYEN stock can currently be purchased for approximately $1.68.

How much money does Eyenovia make?

Eyenovia (NASDAQ:EYEN) has a market capitalization of $64.19 million and generates $14 million in revenue each year. The company earns $-28,010,000.00 in net income (profit) each year or ($0.69) on an earnings per share basis.

How can I contact Eyenovia?

Eyenovia's mailing address is 295 MADISON AVENUE SUITE 2400, NEW YORK NY, 10017. The official website for the company is www.eyenoviabio.com. The company can be reached via phone at (917) 289-1117 or via email at tbui@theruthgroup.com.

This page (NASDAQ:EYEN) was last updated on 9/27/2023 by MarketBeat.com Staff

My Account -